Is Alphabet an Undervalued Growth Stock to Buy?
Alphabet (NASDAQ:GOOGL) is easily one of the most successful companies…
Buy
62
HAE Quote, Financials, Valuation and Earnings
Last price:
$76.29
Seasonality move
:
0.99%
Day range:
$74.49 - $77.48
52-week range:
$70.25 - $97.97
Dividend yield:
0%
P/E ratio:
32.02x
P/S ratio:
2.92x
P/B ratio:
4.41x
Volume:
652.2K
Avg. volume:
602.9K
1-year change:
-12.3%
Market cap:
$3.9B
Revenue:
$1.3B
EPS (TTM):
$2.41
Analysts' Opinion
-
Consensus RatingHaemonetics has received a consensus rating of . The company's average rating is a based on 3 Buy ratings, 2 Hold ratings, and 0 Sell ratings.
-
Price Target UpsideAccording to analysts' consensus price target of $110.80, Haemonetics has an estimated upside of 43.56% from its current price of $77.18.
-
Price Target DownsideAccording to analysts, the lowest downside price target is $85.00 representing 100% downside risk from its current price of $77.18.
Fair Value
-
According to the consensus of 0 analysts, Haemonetics has 43.56% upside to fair value with a price target of $110.80 per share.
HAE vs. S&P 500
-
Over the past 5 trading days, Haemonetics has underperformed the S&P 500 by -7.77% suggesting its relative strength compared to the major market average is weak at this time.
Share Buyback
-
Haemonetics does have a share repurchase program in place at this time. The scale of a buyback program can materially affect share price and usually results in a higher earnings per share, all else being equal, when the share count drops.
Revenue Growth
-
Haemonetics has grown year-over-year revenues for 14 quarters straight. In the most recent quarter Haemonetics reported revenues of $345.5M.
Earnings Growth
-
Haemonetics has grown year-over-year earnings for 1 quarter straight. In the most recent quarter Haemonetics reported earnings per share of $0.66.
Enterprise value:
4.8B
EV / Invested capital:
2.28x
Price / LTM sales:
2.92x
EV / EBIT:
28.69x
EV / Revenue:
3.53x
PEG ratio (5yr expected):
13.19x
EV / Free cash flow:
235.95x
Price / Operating cash flow:
194.97x
Enterprise value / EBITDA:
17.34x
Gross Profit (TTM):
$716.1M
Return On Assets:
5.4%
Net Income Margin (TTM):
9.1%
Return On Equity:
13.51%
Return On Invested Capital:
6.54%
Operating Margin:
14.96%
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2022-09-30 | 2023-09-30 | 2024-09-30 | 2023-09-30 | 2024-09-30 | |
| Income Statement | ||||||
| Revenue | $1.1B | $1.2B | $1.4B | $318.2M | $345.5M | |
| Gross Profit | $575M | $652.7M | $716.1M | $170.5M | $187.4M | |
| Operating Income | $132.3M | $167.1M | $165.4M | $35.3M | $51.7M | |
| EBITDA | $227.4M | $261M | $276.9M | $58.3M | $80.9M | |
| Diluted EPS | $1.66 | $2.49 | $2.41 | $0.48 | $0.66 | |
| Period Ending | 2020-09-30 | 2021-09-30 | 2022-09-30 | 2023-09-30 | 2024-09-30 | |
|---|---|---|---|---|---|---|
| Balance Sheet | ||||||
| Current Assets | $760.3M | $699.2M | $715.8M | $865.7M | $955.9M | |
| Total Assets | $1.4B | $1.8B | $1.9B | $2B | $2.5B | |
| Current Liabilities | $338.6M | $288.5M | $262.2M | $264.2M | $273.9M | |
| Total Liabilities | $750.3M | $1.1B | $1.1B | $1.1B | $1.6B | |
| Total Equity | $667.9M | $698.5M | $729M | $893.7M | $878.9M | |
| Total Debt | $464M | $780.8M | $817.7M | $762.2M | $1.2B | |
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2022-09-30 | 2023-09-30 | 2024-09-30 | 2023-09-30 | 2024-09-30 | |
| Cash Flow Statement | ||||||
| Cash Flow Operations | $259.5M | $262.2M | $84.9M | $99.1M | $48.8M | |
| Cash From Investing | -$139.3M | -$94.9M | -$444.6M | -$25.1M | -$23.4M | |
| Cash From Financing | -$59.9M | -$59.1M | $304.8M | -$7.2M | -$74.8M | |
| Free Cash Flow | $116.3M | $216.7M | $20.4M | $90M | $39.4M | |
HAE
Sector
Market Cap
$3.9B
$45.6M
Price % of 52-Week High
78.78%
45.55%
Dividend Yield
0%
0%
Shareholder Yield
--
-0.74%
1-Year Price Total Return
-12.3%
-31.35%
Beta (5-Year)
0.383
0.772
Dividend yield:
0%
Annualized payout:
$0.00
Payout ratio:
--
Growth streak:
0 years
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Technicals
8-day SMA
Sell
Level
$79.51
200-day SMA
Sell
Level
$82.88
Bollinger Bands (100)
Sell
Level
73.43 - 84.65
Chaikin Money Flow
Buy
Level
60.8M
20-day SMA
Sell
Level
$82.84
Relative Strength Index (RSI14)
Sell
Level
37.79
ADX Line
Sell
Level
19.93
Williams %R
Neutral
Level
-75.8094
50-day SMA
Sell
Level
$81.15
MACD (12, 26)
Sell
Level
-1.54
25-day Aroon Oscillator
Sell
Level
-96
On Balance Volume
Neutral
Level
29.7M
Financial Scores
Buy
Altman Z-Score
(Annual)
Level (3.4348)
Buy
CA Score
(Annual)
Level (-0.1759)
Buy
Beneish M-Score
(Annual)
Level (-2.4187)
Buy
Momentum Score
Level (3)
Buy
Ohlson Score
Level (-0.0604)
Buy
Piotroski F Score
(Annual)
Level (7)
Buy
Quality Ratio Score
Level (5)
Buy
Fundamental Score
Level (7)
Revenue Forecast
Earnings per Share Forecast
Company Profile
Haemonetics Corp aims to improve patient care and reduce the cost of healthcare by providing medical products and solutions in the blood and plasma component collection, surgical suite, and hospital transfusion service spaces. As such, the company operates under three segments: plasma, blood center, and hospital. The company places primary emphasis on its plasma and hospital segments due to their robust growth potential, whereas the blood center segment tends to be constrained by higher competition. Product revenue is driven by demand for disposable blood component collection and processing sets and the related equipment needed for proper functionality.
Stock Forecast FAQ
In the current month, HAE has received 3 Buy ratings 2 Hold ratings, and 0 Sell ratings. The HAE average analyst price target in the past 3 months is $110.80.
-
Where Will Haemonetics Stock Be In 1 Year?
According to analysts, the consensus estimate is that Haemonetics share price will rise to $110.80 per share over the next 12 months.
-
What Do Analysts Say About Haemonetics?
Analysts are divided on their view about Haemonetics share price and where it will be in the next 12 months. The majority of analysts rate the stock a Buy. However, a smaller subset of analysts suggest that Haemonetics is a Sell and believe this share price will drop from its current level to $85.00.
-
What Is Haemonetics's Price Target?
The price target for Haemonetics over the next 1-year time period is forecast to be $110.80 according to 0 Wall Street analysts, 3 of them rate the stock a Buy, 0 rate the stock a Sell, and 2 analysts rate the stock a Hold.
-
Is HAE A Buy, Sell Or Hold?
According to Wall Street analysts, the consensus rating for Haemonetics is a . 0 of 0 analysts rate the stock a at this time.
-
How Can I Buy Shares Of HAE?
You can purchase shares of Haemonetics via an online brokerage firm such as TD Ameritrade.com, thinkorswim.com, e-trade.com, TastyTrade.com, or Schwab.com. Many other digital online brokerages exist such as RobinHood and Webull where you can purchase Haemonetics shares.
-
What Is The Haemonetics Share Price Today?
Haemonetics was last trading at $76.29 per share. This represents the most recent stock quote for Haemonetics. Yesterday, Haemonetics closed at $77.18 per share.
-
How To Buy Haemonetics Stock Online?
In order to purchase Haemonetics stock online, open a brokerage account, deposit funds into the account, and select an order type to purchase shares whether it be market or limit.
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Is Tesla Going to Buy Uber?
Tesla has always been in the habit of making large,…
NVIDIA vs Broadcom Stock: Which Is Best?
If you want to invest in an AI-leading tech company,…
Stock Ideas
Buy
65
Is AAPL Stock a Buy?
Market Cap: $3.9T
P/E Ratio: 42x
Buy
57
Is NVDA Stock a Buy?
Market Cap: $3.4T
P/E Ratio: 117x
Buy
53
Is MSFT Stock a Buy?
Market Cap: $3.2T
P/E Ratio: 37x
Alerts
Sell
40
MSTR alert for Dec 24
MicroStrategy [MSTR] is up 7.34% over the past day.
Sell
26
NUTX alert for Dec 24
Nutex Health [NUTX] is down 0.76% over the past day.
Sell
48
VRNA alert for Dec 24
Verona Pharma PLC [VRNA] is down 0.68% over the past day.
